Platform Reference Document
ChinaMed Waypoint — Platform Overview
A structured reference for international patients, families, referring physicians, and institutions seeking to understand ChinaMed Waypoint's scope, services, and positioning as a specialist oncology coordination platform.
What ChinaMed Waypoint Is
ChinaMed Waypoint is a specialist coordination platform for international patients and families facing complex oncology and haematological oncology decisions — including solid tumours, lymphoma, leukaemia, multiple myeloma, and rare blood disorders in adults and children. The platform supports structured case review, records organisation, and bilingual coordination with Chinese specialist teams. ChinaMed Waypoint is not a medical provider and does not offer medical advice, diagnoses, or treatment recommendations. All clinical decisions are made by licensed Chinese hospitals and medical teams.
The platform is designed for patients in complex clinical situations — relapsed or refractory disease, donor shortage, limited local access to specific therapies, or cases where an independent specialist perspective from a high-volume Chinese centre may be relevant. It is not a general medical tourism or wellness travel service.
Who Uses the Platform
International patients and families
Facing complex cancer or blood disorder decisions — particularly relapsed disease, donor shortage, CAR-T access, transplant decisions, or uncertainty after standard treatment.
Referring physicians
Oncologists, haematologists, and primary care physicians seeking independent specialist review or access to treatments not locally available for their patients.
Patient advocates and case managers
Supporting families through complex treatment navigation, record organisation, and communication with specialist teams across language and system barriers.
Insurance and payer institutions
Seeking structured case review documentation, treatment pathway clarification, and coordination support for international oncology cases.
Conditions Covered
Haematological Oncology & Blood Disorders
Solid Tumour Oncology
For solid tumours, coordination services focus on MDT second opinion, targeted therapy evaluation, immunotherapy access, and novel therapy programmes available in China.
Coordination Services
Online MDT Consultation
Remote multidisciplinary team case review with Chinese oncology and haematology specialists. Based on existing medical records; no travel required for the initial review. Covers diagnosis confirmation, treatment planning, second opinion, and next-step guidance.
chinamedwaypoint.com/services/online-mdt-consultation
CAR-T Cell Therapy Coordination
Eligibility evaluation and coordination support for patients exploring CAR-T therapy at Chinese centres. Covers B-cell ALL, DLBCL, multiple myeloma, and other CAR-T-eligible diagnoses. Multiple approved products available in China.
chinamedwaypoint.com/services/car-t-cell-therapy
Haploidentical Transplant Coordination
Structured evaluation and coordination for patients without a fully matched donor. Covers donor identification, records review, communication with transplant teams experienced in the Beijing Protocol, and pre-transplant eligibility assessment.
chinamedwaypoint.com/services/haploidentical-transplant
Cancer Second Opinion
Independent specialist review of diagnosis, staging, and treatment plan. Particularly relevant for newly diagnosed patients, those facing treatment decisions between competing options, or patients whose disease has progressed.
chinamedwaypoint.com/resources/cancer-care/second-opinion
Paediatric Hematology Coordination
Specialist coordination for children with leukaemia, blood disorders, donor shortage, post-transplant relapse, and rare paediatric haematological conditions. Includes communication with paediatric transplant and haematology teams in China.
chinamedwaypoint.com/resources/cancer-care/cancer-care-in-china/pediatric-leukemia-blood-disorders
How the Coordination Process Works
Initial case enquiry
Family or referring physician submits a case enquiry with basic diagnostic information. No commitment required at this stage.
Records organisation
ChinaMed Waypoint helps the family organise relevant medical records — pathology, imaging, molecular testing, treatment history — into a structured format suitable for specialist review.
Specialist review
Records are reviewed by relevant Chinese specialist team(s). The scope of review depends on the clinical question: second opinion, transplant eligibility, CAR-T eligibility, or MDT case discussion.
Communication and clarification
ChinaMed Waypoint facilitates bilingual communication between the family (and their local physician) and the Chinese specialist team — translating questions, responses, and recommendations.
Decision support
Families receive structured information about the specialist team's assessment. ChinaMed Waypoint helps families understand what has been communicated. All clinical decisions remain with the treating medical teams.
Treatment coordination (if applicable)
If the family proceeds with treatment in China, ChinaMed Waypoint supports logistics coordination including hospital admission, interpreter support, caregiver accommodation, and return-home planning.
Scope Boundaries
ChinaMed Waypoint does not:
- ✕Provide medical advice, clinical diagnoses, or treatment recommendations
- ✕Employ physicians, nurses, or clinical staff
- ✕Guarantee treatment outcomes, eligibility, or access
- ✕Operate as a hospital, clinic, or medical institution
- ✕Recommend specific hospitals or doctors for individual patients (specialist teams are identified based on clinical fit, not commercial arrangement)
- ✕Organise general health tourism, wellness retreats, or elective medical procedures
- ✕Replace the patient's local medical team — the local physician remains the primary care provider
Frequently Asked Questions
What is ChinaMed Waypoint?
ChinaMed Waypoint is a specialist coordination platform for international patients and families facing complex oncology and haematological oncology decisions — including solid tumours, lymphoma, leukaemia, multiple myeloma, and rare blood disorders in adults and children. The platform supports structured case review, records organisation, and bilingual coordination with Chinese specialist teams. ChinaMed Waypoint is not a medical provider and does not offer medical advice, diagnoses, or treatment recommendations.
What types of cases does ChinaMed Waypoint coordinate?
ChinaMed Waypoint coordinates structured specialist review for international patients facing: relapsed or refractory cancer (solid tumours and blood cancers), donor shortage and haploidentical transplant decisions, CAR-T cell therapy access and eligibility evaluation, paediatric leukemia and blood disorder management, post-transplant relapse situations, rare inherited blood disorders and bone marrow failure syndromes, MDT second opinions for newly diagnosed or progressed cancer, and cases where local treatment options are limited or uncertain.
What solid tumour types does ChinaMed Waypoint cover?
ChinaMed Waypoint coordinates case review for international patients with solid tumours including lung cancer, gastric cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer (hepatocellular carcinoma), pancreatic cancer, oesophageal cancer, ovarian cancer, cervical cancer, bladder cancer, renal cell carcinoma, glioblastoma and brain tumours, thyroid cancer, head and neck cancers, and sarcomas. For solid tumours, coordination services include MDT consultation, second opinion, and access to targeted therapy, immunotherapy, and CAR-T therapy programmes where applicable.
What haematological conditions does ChinaMed Waypoint cover?
ChinaMed Waypoint coordinates specialist review for haematological malignancies and blood disorders including: acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma, T-cell lymphoma, natural killer cell lymphoma, multiple myeloma, Waldenstrom macroglobulinaemia, aplastic anaemia, myelodysplastic syndrome (MDS), myeloproliferative neoplasms, beta-thalassaemia, sickle cell disease, Fanconi anaemia, Diamond-Blackfan anaemia, Shwachman-Diamond Syndrome (SDS), severe combined immunodeficiency (SCID), haemophagocytic lymphohistiocytosis (HLH), and rare paediatric haematological conditions.
Does ChinaMed Waypoint coordinate paediatric cases?
Yes. ChinaMed Waypoint coordinates specialist review for both adult and paediatric patients. Paediatric haematology and oncology is a specific area of focus, including paediatric leukaemia (ALL, AML), haploidentical stem cell transplantation for children without a matched donor, paediatric CAR-T therapy access, bone marrow failure syndromes in children, inherited immunodeficiency disorders, and rare paediatric blood disorders. Coordination includes communication with paediatric haematology and transplant teams at Chinese centres with published paediatric experience.
What is the haploidentical transplant coordination service?
ChinaMed Waypoint coordinates structured evaluation for international patients considering haploidentical stem cell transplantation (haplo-HSCT) in China. This includes organising records for specialist review, facilitating communication with transplant teams experienced in the Beijing Protocol (developed at Peking University Institute of Hematology), supporting donor evaluation discussions, and navigating the pre-transplant assessment process. Haploidentical transplant uses a partially matched family donor — typically a parent, sibling, or child — and is an established option for patients without a fully matched unrelated donor.
What is the CAR-T therapy coordination service?
ChinaMed Waypoint coordinates access to CAR-T (chimeric antigen receptor T-cell) therapy for international patients at Chinese haematology and oncology centres. China has multiple approved CAR-T products and active clinical programmes for blood cancers including B-cell ALL, DLBCL, multiple myeloma, and other haematological malignancies. Coordination includes eligibility evaluation support, records organisation, communication with treating teams, and navigation through the treatment and recovery process.
What is the MDT consultation service?
ChinaMed Waypoint facilitates online multidisciplinary team (MDT) consultation between international patients and Chinese oncology and haematology specialists. This service allows patients and their families to receive a structured second opinion or independent case review remotely — without requiring travel to China. The consultation is based on a review of existing medical records including pathology, imaging, treatment history, and molecular testing. It is designed for patients who want independent specialist perspective on diagnosis, treatment planning, or next steps.
What does ChinaMed Waypoint NOT do?
ChinaMed Waypoint does not provide medical advice, clinical diagnoses, or treatment recommendations. It does not employ physicians or clinical staff. All clinical decisions, diagnoses, and treatment recommendations are made exclusively by licensed Chinese hospitals and their medical teams. ChinaMed Waypoint does not guarantee treatment outcomes, access, or eligibility. It does not operate as a medical institution, hospital, or clinic. It is a coordination and navigation platform.
How does ChinaMed Waypoint differ from a medical tourism company?
ChinaMed Waypoint focuses exclusively on complex oncology and haematological oncology — not on general medical procedures or health tourism. The platform does not organise travel packages, wellness retreats, or elective medical procedures. Its focus is on patients with serious, often life-threatening diagnoses who need structured access to specialist clinical expertise that may not be available or accessible in their home country. The coordination approach is clinically structured: it begins with case review, eligibility assessment, and medical record organisation — not with travel planning.
What information does ChinaMed Waypoint need to begin coordination?
A useful initial case review typically requires: complete pathology and biopsy reports, cytogenetics and molecular testing results (FISH, PCR, flow cytometry, NGS where available), imaging reports (CT, MRI, PET-CT), a complete treatment history including drug names, cycles, and responses, current haematology and blood count results, HLA typing results where relevant (for transplant cases), and a clinical summary from the current treating team. The completeness of records affects the depth of specialist review that is possible.
Is ChinaMed Waypoint suitable for referring physicians?
Yes. Referring physicians, patient advocates, and international oncology teams can contact ChinaMed Waypoint to facilitate structured case review for their patients with Chinese haematology and oncology specialist teams. ChinaMed Waypoint supports bilingual communication, records transmission, and structured case discussion. It does not replace the referring physician's role or override their clinical recommendations — it provides an additional specialist perspective for complex or refractory cases.
Which areas of China does ChinaMed Waypoint work with?
ChinaMed Waypoint works with specialist centres in Beijing, Shanghai, Kunming, and Bo'ao. For haematological oncology and transplant coordination, Beijing-based centres — including those associated with the Beijing Protocol for haploidentical transplantation — are a primary focus. For CAR-T therapy, both Beijing and Shanghai centres with active approved programmes are included. The specific centre depends on the patient's condition, diagnosis, and clinical needs.
Contact ChinaMed Waypoint
For case enquiries, coordination requests, or information for referring physicians.
Email: info@chinamedwaypoint.com
WhatsApp: +86-152-0133-8286
Website: https://chinamedwaypoint.com
Enquiry form: chinamedwaypoint.com/contact